Divya is freshman at Northeastern University and will be joining the laboratory to study novel antimicrobial treatment strategies. Her first project will involve collaboration with our Beth Israel Deaconess Medical Center and Harvard Medical School pathology colleague, Anders Berg.
Our Gram stain artificial intelligence platform was selected as a competitor in the 2018 Stat Madness Competition.
Work from our laboratory was selected as a competitor in the 2018 StatMadness Competition. This bracket style national competition will allow voters to choose among important medical innovations developed at selected medical centers and universities across the United States. The artificial intelligence-based-platform named Technologist Assist allows automatic imaging and interpretation of Gram stain results and ultimately will provide assisted laboratory diagnostic capabilities at near or remote sites.
Please vote for our work at the Stat Madness website: www.statnews.com/feature/stat-madness/bracket/
We officially moved the lab today. Not very far. Just to other side of the floor. Doubled our bench space! We are all very excited!
Congratulations to Thea Brennan-Krohn on being awarded a five year K08 Mentored Clinical Scientist Research Career Development Award by the National Institutes of Health!
Research Associate Position | MAST | Beth Israel Deaconess Medical Center | Boston | Kirby Laboratory | Harvard Medical School
Seeking to hire a research associate to work on the MAST project (microscopy-based antimicrobial susceptibility testing. Please contact email@example.com and send a c.v., short statement of interest, and contact information for three references. The official BIDMC official posting is in the described as a research assistant in the pathology department.
Congratulations to lab members, Anthony Kang, and colleagues for our manuscript newly accepted in Antimicrobial Agents and Chemotherapy titled: "Efficacy of Apramycin against Multidrug-Resistant Acinetobacter baumannii in the Murine Neutropenic Thigh Model"
The manuscripts describes potent in vitro and in vivo activity of the apramycin, an aminocyclitol aminoglycoside, against multidrug-resistant and extensively-drug resistant Acinetobacter baumannii.
In prior manuscripts, we demonstrated broad activity against several types of multidrug-resistant pathogens including carbapenem-resistant Enterobacteriaceae (CRE), Acinetobacter baumannii and Pseudomonas aeruginosa
The laboratory has been fortunate to participate in Harvard Catalyst Reactor Program through the "Big Ideas, Small Features” Pilot Grant Award. A description of the program was recently published last week in Harvard Medical School news titled "Catalyzing Research Innovation."
A description of the supported work can be found at: "Reactor Program Awards Eight New Pilot Grants: Supports researchers with novel solutions to major clinical challenges."
Updates on lab activities